Short-term cost of interferon-free therapies for all HCV patients high yet cost-effective
January 9, 2017
A recent cost-effective analysis evaluating the value of interferon-free therapies for the treatment of hepatitis C virus infection genotype 1 revealed that administering less expensive regimens to non-cirrhotic patients and expensive yet more effective regimens to cirrhotic patients resulted in optimal outcomes for patients and insurers. Meanwhile, limiting treatment only to those with more advanced disease often resulted in poor outcomes, according to researchers.
Continue reading....
No comments:
Post a Comment